Preliminary Results from Poseida’s P-PSMA-101 (PSMA CAR-T) Ph1 Trial in mCRPC; FDA Accepts Poseida’s P-BCMA-ALLO1 (Allogeneic BCMA CAR-T) IND in R/R MM
On Tuesday, August 31, Poseida presented (press release / webcast) preliminary results from P-PSMA-101’s (PSMA CAR-T) Ph1 trial in metastatic castration-resistant prostate cancer (mCRPC). Additionally, on Monday, August 30, Poseida announced (press release) that the FDA has accepted an IND application for P-BCMA-ALLO1 (allogeneic BCMA CAR-T) in r/r MM. Below, Celltelligence provides insights on how Poseida’s novel technology may be a key differentiating factor for the successful development of P-PSMA-101, while discussing Poseida’s position in the race to develop an allogeneic BCMA CAR-T for r/r MM.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.